Heat Biologics (HTBX) Lifted to Sell at ValuEngine

Heat Biologics (NASDAQ:HTBX) was upgraded by equities research analysts at ValuEngine from a “strong sell” rating to a “sell” rating in a research note issued to investors on Wednesday.

Shares of Heat Biologics (NASDAQ HTBX) opened at $2.93 on Wednesday. The company has a market cap of $104.86, a P/E ratio of -0.70 and a beta of 0.69. Heat Biologics has a 1 year low of $2.62 and a 1 year high of $12.50.

Heat Biologics (NASDAQ:HTBX) last issued its quarterly earnings results on Monday, November 13th. The biopharmaceutical company reported ($0.60) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.90) by $0.30. The firm had revenue of $0.47 million for the quarter, compared to the consensus estimate of $0.50 million. Heat Biologics had a negative net margin of 1,184.92% and a negative return on equity of 149.69%. equities research analysts expect that Heat Biologics will post -2.53 EPS for the current year.

A hedge fund recently raised its stake in Heat Biologics stock. Vanguard Group Inc. raised its position in Heat Biologics, Inc. (NASDAQ:HTBX) by 11.9% during the second quarter, according to its most recent filing with the SEC. The firm owned 661,388 shares of the biopharmaceutical company’s stock after purchasing an additional 70,290 shares during the period. Vanguard Group Inc. owned 1.86% of Heat Biologics worth $403,000 as of its most recent filing with the SEC. Hedge funds and other institutional investors own 7.85% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally posted by Transcript Daily and is the property of of Transcript Daily. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The correct version of this piece of content can be read at https://transcriptdaily.com/2018/01/24/heat-biologics-htbx-lifted-to-sell-at-valuengine.html.

About Heat Biologics

Heat Biologics, Inc is a development-stage company focused on developing allogeneic, off-the-shelf cellular therapeutic vaccines to combat a range of cancers. The Company is an immuno-oncology company, which focuses on T cell-stimulating platform technologies, such as Immune Pan-Antigen Cytotoxic Therapy (ImPACT) and Combination Pan-Antigen Cytotoxic Therapy (ComPACT).

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Heat Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heat Biologics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply